ダイレクト・トゥ・コンシューマー・ラボラトリー検査市場(検査タイプ。遺伝子検査、疾病リスク評価検査、CBC、慢性疾患検査、COVID-19検査、TSH検査、その他;サンプルタイプ。検査タイプ:血液、唾液、尿、その他;プロバイダー:。欧州の産業分析、サイズ、シェア、成長、傾向、予測、2021-2031年Direct-to-Consumer Laboratory Testing Market (Test Type: Genetic Testing, Disease Risk Assessment Testing, CBC, Chronic Disease Testing, COVID-19 Testing, TSH Testing, and Others; Sample Type: Blood, Saliva, Urine, and Others; and Provider: Hospitals, Clinics, Specialty Labs, and Diagnostic Centers) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 欧州のダイレクト・ツー・コンシューマー・ラボラトリー検査市場 - レポートの範囲 TMRの調査レポート「欧州の消費者向け直接検査市場」は、2021年から2031年までの予測期間における市場の指標に関する貴重な... もっと見る
サマリー欧州のダイレクト・ツー・コンシューマー・ラボラトリー検査市場 - レポートの範囲TMRの調査レポート「欧州の消費者向け直接検査市場」は、2021年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。本レポートでは、2020年を基準年、2031年を予測年として、2017年から2031年までの欧州の消費者直販型ラボラトリーテスト市場の売上高を提供しています。また、予測期間における欧州の消費者向け直接検査市場の複合年間成長率(CAGR)を記載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、アナリストが業界のリーダーやオピニオンメーカーにインタビューを行うなど、大規模な調査活動を行いました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、欧州の消費者直販型ラボ検査市場を理解するために実施しました。 二次調査には、インターネット上の情報源、政府機関の統計データ、ウェブサイト、業界団体も含まれます。アナリストは、欧州の消費者直販型ラボ検査市場における様々な現象を研究するために、トップダウンとボトムアップのアプローチを組み合わせて採用しました。 本レポートには、精緻なエグゼクティブサマリー、調査範囲に含まれる様々なセグメントの成長挙動に関するスナップショットが含まれています。さらに、欧州の消費者直販型ラボ検査市場における競争力学の変化についても光を当てています。これらの指標は、既存の市場関係者だけでなく、欧州の消費者向けラボラトリーテスト市場への参入に関心を持つ事業者にとっても貴重なツールになります。消費者直接検査市場レポートの次のセクションでは、主要産業イベント(ライセンス提携/M&A)、地域/国別の疾患疫学、COVID-19パンデミックの産業への影響(バリューチェーンと短期/中期/長期の影響)、ヨーロッパの消費者直接検査市場で事業を行うトッププレイヤーの主要成功要因などのUSPをハイライトしています。 また、欧州の消費者向け直接検査市場の競争環境についても掘り下げています。欧州の消費者直販型ラボラトリーテスト市場で活動する主要企業が特定され、これらの各企業は特徴的なビジネス属性についてプロファイルされています。会社概要、財務状況、最近の開発、戦略的概要、SWOTは、本レポートで紹介された欧州の消費者向け直接検査市場におけるプレーヤーの属性の一部です。 欧州の消費者向けラボラトリーテストの市場レポートで回答された主要な質問 市場の主な推進要因、阻害要因、機会は何か? 欧州の消費者直販型ラボ検査市場における予測期間中の主要セグメントの収益シェア予測は? 2031年までに欧州の消費者直販型ラボラトリーテスト市場を収益面でリードするのはどのセグメントか? 技術開発によって欧州の消費者直販型ラボラトリーテスト市場の範囲はどのように広がっているのか? 欧州の消費者直販型ラボラトリーテスト市場で事業を展開する各企業の市場地位はどうなっているのか? 欧州の消費者直販型ラボラトリーテスト市場 - 調査目的と調査方法 欧州の消費者向け直接検査市場に関する包括的なレポートは、まず市場の概要を説明し、次に本調査の範囲と目的について述べます。これに続いて、本調査の目的および欧州の消費者直販型ラボラトリー検査市場の調査範囲において認定機関が定めた医療コンプライアンスについて詳細に説明しています。続いて、市場導入、市場力学、欧州の消費者直接検査市場の概要が記載されており、欧州の消費者直接検査市場の成長に影響を与える市場促進要因、阻害要因、機会に関するTMR分析が記載されています。さらに、欧州の消費者直販ラボラトリーテスト市場のYo-Yトレンドを理解するために、精巧な洞察によるYo-Y分析が提供されています。 本レポートは、読みやすさを考慮し、各セクションを細分化した章立てで編集されています。レポート全体は、グラフと表が適切に配置された網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を絵で表現することで、読者に視覚的にアピールしています。これにより、過去と予測期間終了時の主要セグメントの市場シェアを比較することができます。 本レポートでは、欧州の消費者向け直接検査市場を、検査タイプ、サンプルタイプ、プロバイダ、国の観点から分析しています。各基準における主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアも掲載しています。このような貴重な洞察は、市場関係者が消費者直接ラボラトリー検査市場への投資について、情報に基づいたビジネス上の意思決定を行うことを可能にします。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Europe Direct-to-Consumer Laboratory Testing Market 4. Market Overview 4.1. Introduction 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, 2017–2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Key Industrial Events (licensing partnerships/mergers & acquisitions) 5.2. Disease Prevalence & Incidence Rate 5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact) 6. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Sample Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Sample Type, 2017–2031 6.3.1. Blood 6.3.2. Urine 6.3.3. Saliva 6.3.4. Others 6.4. Market Attractiveness Analysis, by Sample Type 7. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Test Type 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Test Type, 2017–2031 7.3.1. Genetic Testing 7.3.1.1. Nutrigenetics Test 7.3.1.1.1. Weight Control 7.3.1.1.2. Lactose Intolerance 7.3.1.1.3. Others 7.3.1.2. Celiac Disease Test 7.3.1.3. Sports & Physical Activity Testing 7.3.1.4. Men's Health Tests 7.3.1.5. Women's Health Tests 7.3.1.6. Pregnancy & Prenatal Screening Test 7.3.1.7. General Health Testing 7.3.1.8. Others 7.3.2. Disease Risk Assessment Testing 7.3.2.1. Sexual Health Tests 7.3.2.1.1. HIV 7.3.2.1.2. Chlamydia 7.3.2.1.3. Others 7.3.2.2. Cancer Predisposition Tests 7.3.2.3. Others 7.3.3. CBC 7.3.4. Chronic Disease Testing 7.3.4.1. Diabetes Testing 7.3.4.2. Hypertension 7.3.4.3. Others 7.3.5. COVID-19 Testing 7.3.6. TSH Testing 7.3.7. Others 7.4. Market Attractiveness Analysis, by Test Type 8. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Provider 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Provider, 2017–2031 8.3.1. Hospitals 8.3.2. Clinics 8.3.3. Speciality Labs 8.3.4. Diagnostic Centres 8.4. Market Attractiveness Analysis, by Provider 9. Germany Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. Market Value Forecast, by Sample Type, 2017–2031 9.2.1. Blood 9.2.2. Urine 9.2.3. Saliva 9.2.4. Others 9.3. Market Value Forecast, by Test Type, 2017–2031 9.3.1. Genetic Testing 9.3.1.1. Nutrigenetics Test 9.3.1.1.1. Weight Control 9.3.1.1.2. Lactose Intolerance 9.3.1.1.3. Others 9.3.1.2. Celiac Disease Test 9.3.1.3. Sports & Physical Activity Testing 9.3.1.4. Men's Health Tests 9.3.1.5. Women's Health Tests 9.3.1.6. Pregnancy & Prenatal Screening Test 9.3.1.7. General Health Testing 9.3.1.8. Others 9.3.2. Disease Risk Assessment Testing 9.3.2.1. Sexual Health Tests 9.3.2.1.1. HIV 9.3.2.1.2. Chlamydia 9.3.2.1.3. Others 9.3.2.2. Cancer Predisposition Tests 9.3.2.3. Others 9.3.3. CBC 9.3.4. Chronic Disease Testing 9.3.4.1. Diabetes Testing 9.3.4.2. Hypertension 9.3.4.3. Others 9.3.5. COVID-19 Testing 9.3.6. TSH Testing 9.3.7. Others 9.4. Market Value Forecast, by Provider, 2017–2031 9.4.1. Hospitals 9.4.2. Clinics 9.4.3. Speciality Labs 9.4.4. Diagnostic Centres 10. U.K. Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Sample Type, 2017–2031 10.2.1. Blood 10.2.2. Urine 10.2.3. Saliva 10.2.4. Others 10.3. Market Value Forecast, by Test Type, 2017–2031 10.3.1. Genetic Testing 10.3.1.1. Nutrigenetics Test 10.3.1.1.1. Weight Control 10.3.1.1.2. Lactose Intolerance 10.3.1.1.3. Others 10.3.1.2. Celiac Disease Test 10.3.1.3. Sports & Physical Activity Testing 10.3.1.4. Men's Health Tests 10.3.1.5. Women's Health Tests 10.3.1.6. Pregnancy & Prenatal Screening Test 10.3.1.7. General Health Testing 10.3.1.8. Others 10.3.2. Disease Risk Assessment Testing 10.3.2.1. Sexual Health Tests 10.3.2.1.1. HIV 10.3.2.1.2. Chlamydia 10.3.2.1.3. Others 10.3.2.2. Cancer Predisposition Tests 10.3.2.3. Others 10.3.2.4. CBC 10.3.2.5. Chronic Disease Testing 10.3.2.5.1. Diabetes Testing 10.3.2.5.2. Hypertension 10.3.2.5.3. Others 10.3.2.6. COVID-110 Testing 10.3.2.7. TSH Testing 10.3.2.8. Others 10.4. Market Value Forecast, by Provider, 2017–2031 10.4.1. Hospitals 10.4.2. Clinics 10.4.3. Speciality Labs 10.4.4. Diagnostic Centres 11. France Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Sample Type, 2017–2031 11.2.1. Blood 11.2.2. Urine 11.2.3. Saliva 11.2.4. Others 11.3. Market Value Forecast, by Test Type, 2017–2031 11.3.1. Genetic Testing 11.3.1.1. Nutrigenetics Test 11.3.1.1.1. Weight Control 11.3.1.1.2. Lactose Intolerance 11.3.1.1.3. Others 11.3.1.2. Celiac Disease Test 11.3.1.3. Sports & Physical Activity Testing 11.3.1.4. Men's Health Tests 11.3.1.5. Women's Health Tests 11.3.1.6. Pregnancy & Prenatal Screening Test 11.3.1.7. General Health Testing 11.3.1.8. Others 11.3.2. Disease Risk Assessment Testing 11.3.2.1. Sexual Health Tests 11.3.2.1.1. HIV 11.3.2.1.2. Chlamydia 11.3.2.1.3. Others 11.3.2.2. Cancer Predisposition Tests 11.3.2.3. Others 11.3.3. CBC 11.3.4. Chronic Disease Testing 11.3.4.1. Diabetes Testing 11.3.4.2. Hypertension 11.3.4.3. Others 11.3.5. COVID-19 Testing 11.3.6. TSH Testing 11.3.7. Others 11.4. Market Value Forecast, by Provider, 2017–2031 11.4.1. Hospitals 11.4.2. Clinics 11.4.3. Speciality Labs 11.4.4. Diagnostic Centres 12. Italy Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Sample Type, 2017–2031 12.2.1. Blood 12.2.2. Urine 12.2.3. Saliva 12.2.4. Others 12.3. Market Value Forecast, by Test Type, 2017–2031 12.3.1. Genetic Testing 12.3.1.1. Nutrigenetics Test 12.3.1.1.1. Weight Control 12.3.1.1.2. Lactose Intolerance 12.3.1.1.3. Others 12.3.1.2. Celiac Disease Test 12.3.1.3. Sports & Physical Activity Testing 12.3.1.4. Men's Health Tests 12.3.1.5. Women's Health Tests 12.3.1.6. Pregnancy & Prenatal Screening Test 12.3.1.7. General Health Testing 12.3.1.8. Others 12.3.2. Disease Risk Assessment Testing 12.3.2.1. Sexual Health Tests 12.3.2.1.1. HIV 12.3.2.1.2. Chlamydia 12.3.2.1.3. Others 12.3.2.2. Cancer Predisposition Tests 12.3.2.3. Others 12.3.3. CBC 12.3.4. Chronic Disease Testing 12.3.4.1. Diabetes Testing 12.3.4.2. Hypertension 12.3.4.3. Others 12.3.5. COVID-19 Testing 12.3.6. TSH Testing 12.3.7. Others 12.4. Market Value Forecast, by Provider, 2017–2031 12.4.1. Hospitals 12.4.2. Clinics 12.4.3. Speciality Labs 12.4.4. Diagnostic Centres 13. Spain Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Sample Type, 2017–2031 13.2.1. Blood 13.2.2. Urine 13.2.3. Saliva 13.2.4. Others 13.3. Market Value Forecast, by Test Type, 2017–2031 13.3.1. Genetic Testing 13.3.1.1. Nutrigenetics Test 13.3.1.1.1. Weight Control 13.3.1.1.2. Lactose Intolerance 13.3.1.1.3. Others 13.3.1.2. Celiac Disease Test 13.3.1.3. Sports & Physical Activity Testing 13.3.1.4. Men's Health Tests 13.3.1.5. Women's Health Tests 13.3.1.6. Pregnancy & Prenatal Screening Test 13.3.1.7. General Health Testing 13.3.1.8. Others 13.3.2. Disease Risk Assessment Testing 13.3.2.1. Sexual Health Tests 13.3.2.1.1. HIV 13.3.2.1.2. Chlamydia 13.3.2.1.3. Others 13.3.2.2. Cancer Predisposition Tests 13.3.2.3. Others 13.3.3. CBC 13.3.4. Chronic Disease Testing 13.3.4.1. Diabetes Testing 13.3.4.2. Hypertension 13.3.4.3. Others 13.3.5. COVID-19 Testing 13.3.6. TSH Testing 13.3.7. Others 13.4. Market Value Forecast, by Provider, 2017–2031 13.4.1. Hospitals 13.4.2. Clinics 13.4.3. Speciality Labs 13.4.4. Diagnostic Centres 14. Rest of Europe Countries Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Sample Type, 2017–2031 14.2.1. Blood 14.2.2. Urine 14.2.3. Saliva 14.2.4. Others 14.3. Market Value Forecast, by Test Type, 2017–2031 14.3.1. Genetic Testing 14.3.1.1. Nutrigenetics Test 14.3.1.1.1. Weight Control 14.3.1.1.2. Lactose Intolerance 14.3.1.1.3. Others 14.3.1.2. Celiac Disease Test 14.3.1.3. Sports & Physical Activity Testing 14.3.1.4. Men's Health Tests 14.3.1.5. Women's Health Tests 14.3.1.6. Pregnancy & Prenatal Screening Test 14.3.1.7. General Health Testing 14.3.1.8. Others 14.3.2. Disease Risk Assessment Testing 14.3.2.1. Sexual Health Tests 14.3.2.1.1. HIV 14.3.2.1.2. Chlamydia 14.3.2.1.3. Others 14.3.2.2. Cancer Predisposition Tests 14.3.2.3. Others 14.3.3. CBC 14.3.4. Chronic Disease Testing 14.3.4.1. Diabetes Testing 14.3.4.2. Hypertension 14.3.4.3. Others 14.3.5. COVID-19 Testing 14.3.6. TSH Testing 14.3.7. Others 14.4. Market Value Forecast, by Provider, 2017–2031 14.4.1. Hospitals 14.4.2. Clinics 14.4.3. Speciality Labs 14.4.4. Diagnostic Centres 15. Competition Landscape 15.1. Market Player - Competition Matrix (by tier and size of companies) 15.2. Company Profiles 15.2.1. 23andMe, Inc. 15.2.1.1. Company Description 15.2.1.2. Business Overview 15.2.1.3. Strategic Overview 15.2.1.4. SWOT Analysis 15.2.2. Ancestry 15.2.2.1. Company Description 15.2.2.2. Business Overview 15.2.2.3. SWOT Analysis 15.2.3. CircleDNA 15.2.3.1. Company Description 15.2.3.2. Business Overview 15.2.3.3. SWOT Analysis 15.2.4. Eurofins Scientific 15.2.4.1. Company Description 15.2.4.2. Business Overview 15.2.4.3. Financial Overview 15.2.4.4. SWOT Analysis 15.2.5. Family Tree DNA (Gene by Gene) 15.2.5.1. Company Description 15.2.5.2. Business Overview 15.2.5.3. SWOT Analysis 15.2.6. Laboratory Corporation of America Holdings 15.2.6.1. Company Description 15.2.6.2. Business Overview 15.2.6.3. Financial Overview 15.2.6.4. Strategic Overview 15.2.6.5. SWOT Analysis 15.2.7. Living DNA Ltd. 15.2.7.1. Company Description 15.2.7.2. Business Overview 15.2.7.3. SWOT Analysis 15.2.8. Medichecks.com Ltd. 15.2.8.1. Company Description 15.2.8.2. Business Overview 15.2.8.3. SWOT Analysis 15.2.9. MyHeritage Ltd. 15.2.9.1. Company Description 15.2.9.2. Business Overview 15.2.9.3. SWOT Analysis 15.2.10. MyMedLab, Inc. 15.2.10.1. Company Description 15.2.10.2. Business Overview 15.2.10.3. SWOT Analysis 15.2.11. Quest Diagnostics Incorporated 15.2.11.1. Company Description 15.2.11.2. Business Overview 15.2.11.3. Financial Overview 15.2.11.4. Strategic Overview 15.2.11.5. SWOT Analysis
SummaryEurope Direct-to-Consumer Laboratory Testing Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Europe Direct-to-Consumer Laboratory Testing Market 4. Market Overview 4.1. Introduction 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, 2017–2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Key Industrial Events (licensing partnerships/mergers & acquisitions) 5.2. Disease Prevalence & Incidence Rate 5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact) 6. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Sample Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Sample Type, 2017–2031 6.3.1. Blood 6.3.2. Urine 6.3.3. Saliva 6.3.4. Others 6.4. Market Attractiveness Analysis, by Sample Type 7. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Test Type 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Test Type, 2017–2031 7.3.1. Genetic Testing 7.3.1.1. Nutrigenetics Test 7.3.1.1.1. Weight Control 7.3.1.1.2. Lactose Intolerance 7.3.1.1.3. Others 7.3.1.2. Celiac Disease Test 7.3.1.3. Sports & Physical Activity Testing 7.3.1.4. Men's Health Tests 7.3.1.5. Women's Health Tests 7.3.1.6. Pregnancy & Prenatal Screening Test 7.3.1.7. General Health Testing 7.3.1.8. Others 7.3.2. Disease Risk Assessment Testing 7.3.2.1. Sexual Health Tests 7.3.2.1.1. HIV 7.3.2.1.2. Chlamydia 7.3.2.1.3. Others 7.3.2.2. Cancer Predisposition Tests 7.3.2.3. Others 7.3.3. CBC 7.3.4. Chronic Disease Testing 7.3.4.1. Diabetes Testing 7.3.4.2. Hypertension 7.3.4.3. Others 7.3.5. COVID-19 Testing 7.3.6. TSH Testing 7.3.7. Others 7.4. Market Attractiveness Analysis, by Test Type 8. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Provider 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Provider, 2017–2031 8.3.1. Hospitals 8.3.2. Clinics 8.3.3. Speciality Labs 8.3.4. Diagnostic Centres 8.4. Market Attractiveness Analysis, by Provider 9. Germany Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. Market Value Forecast, by Sample Type, 2017–2031 9.2.1. Blood 9.2.2. Urine 9.2.3. Saliva 9.2.4. Others 9.3. Market Value Forecast, by Test Type, 2017–2031 9.3.1. Genetic Testing 9.3.1.1. Nutrigenetics Test 9.3.1.1.1. Weight Control 9.3.1.1.2. Lactose Intolerance 9.3.1.1.3. Others 9.3.1.2. Celiac Disease Test 9.3.1.3. Sports & Physical Activity Testing 9.3.1.4. Men's Health Tests 9.3.1.5. Women's Health Tests 9.3.1.6. Pregnancy & Prenatal Screening Test 9.3.1.7. General Health Testing 9.3.1.8. Others 9.3.2. Disease Risk Assessment Testing 9.3.2.1. Sexual Health Tests 9.3.2.1.1. HIV 9.3.2.1.2. Chlamydia 9.3.2.1.3. Others 9.3.2.2. Cancer Predisposition Tests 9.3.2.3. Others 9.3.3. CBC 9.3.4. Chronic Disease Testing 9.3.4.1. Diabetes Testing 9.3.4.2. Hypertension 9.3.4.3. Others 9.3.5. COVID-19 Testing 9.3.6. TSH Testing 9.3.7. Others 9.4. Market Value Forecast, by Provider, 2017–2031 9.4.1. Hospitals 9.4.2. Clinics 9.4.3. Speciality Labs 9.4.4. Diagnostic Centres 10. U.K. Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Sample Type, 2017–2031 10.2.1. Blood 10.2.2. Urine 10.2.3. Saliva 10.2.4. Others 10.3. Market Value Forecast, by Test Type, 2017–2031 10.3.1. Genetic Testing 10.3.1.1. Nutrigenetics Test 10.3.1.1.1. Weight Control 10.3.1.1.2. Lactose Intolerance 10.3.1.1.3. Others 10.3.1.2. Celiac Disease Test 10.3.1.3. Sports & Physical Activity Testing 10.3.1.4. Men's Health Tests 10.3.1.5. Women's Health Tests 10.3.1.6. Pregnancy & Prenatal Screening Test 10.3.1.7. General Health Testing 10.3.1.8. Others 10.3.2. Disease Risk Assessment Testing 10.3.2.1. Sexual Health Tests 10.3.2.1.1. HIV 10.3.2.1.2. Chlamydia 10.3.2.1.3. Others 10.3.2.2. Cancer Predisposition Tests 10.3.2.3. Others 10.3.2.4. CBC 10.3.2.5. Chronic Disease Testing 10.3.2.5.1. Diabetes Testing 10.3.2.5.2. Hypertension 10.3.2.5.3. Others 10.3.2.6. COVID-110 Testing 10.3.2.7. TSH Testing 10.3.2.8. Others 10.4. Market Value Forecast, by Provider, 2017–2031 10.4.1. Hospitals 10.4.2. Clinics 10.4.3. Speciality Labs 10.4.4. Diagnostic Centres 11. France Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Sample Type, 2017–2031 11.2.1. Blood 11.2.2. Urine 11.2.3. Saliva 11.2.4. Others 11.3. Market Value Forecast, by Test Type, 2017–2031 11.3.1. Genetic Testing 11.3.1.1. Nutrigenetics Test 11.3.1.1.1. Weight Control 11.3.1.1.2. Lactose Intolerance 11.3.1.1.3. Others 11.3.1.2. Celiac Disease Test 11.3.1.3. Sports & Physical Activity Testing 11.3.1.4. Men's Health Tests 11.3.1.5. Women's Health Tests 11.3.1.6. Pregnancy & Prenatal Screening Test 11.3.1.7. General Health Testing 11.3.1.8. Others 11.3.2. Disease Risk Assessment Testing 11.3.2.1. Sexual Health Tests 11.3.2.1.1. HIV 11.3.2.1.2. Chlamydia 11.3.2.1.3. Others 11.3.2.2. Cancer Predisposition Tests 11.3.2.3. Others 11.3.3. CBC 11.3.4. Chronic Disease Testing 11.3.4.1. Diabetes Testing 11.3.4.2. Hypertension 11.3.4.3. Others 11.3.5. COVID-19 Testing 11.3.6. TSH Testing 11.3.7. Others 11.4. Market Value Forecast, by Provider, 2017–2031 11.4.1. Hospitals 11.4.2. Clinics 11.4.3. Speciality Labs 11.4.4. Diagnostic Centres 12. Italy Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Sample Type, 2017–2031 12.2.1. Blood 12.2.2. Urine 12.2.3. Saliva 12.2.4. Others 12.3. Market Value Forecast, by Test Type, 2017–2031 12.3.1. Genetic Testing 12.3.1.1. Nutrigenetics Test 12.3.1.1.1. Weight Control 12.3.1.1.2. Lactose Intolerance 12.3.1.1.3. Others 12.3.1.2. Celiac Disease Test 12.3.1.3. Sports & Physical Activity Testing 12.3.1.4. Men's Health Tests 12.3.1.5. Women's Health Tests 12.3.1.6. Pregnancy & Prenatal Screening Test 12.3.1.7. General Health Testing 12.3.1.8. Others 12.3.2. Disease Risk Assessment Testing 12.3.2.1. Sexual Health Tests 12.3.2.1.1. HIV 12.3.2.1.2. Chlamydia 12.3.2.1.3. Others 12.3.2.2. Cancer Predisposition Tests 12.3.2.3. Others 12.3.3. CBC 12.3.4. Chronic Disease Testing 12.3.4.1. Diabetes Testing 12.3.4.2. Hypertension 12.3.4.3. Others 12.3.5. COVID-19 Testing 12.3.6. TSH Testing 12.3.7. Others 12.4. Market Value Forecast, by Provider, 2017–2031 12.4.1. Hospitals 12.4.2. Clinics 12.4.3. Speciality Labs 12.4.4. Diagnostic Centres 13. Spain Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Sample Type, 2017–2031 13.2.1. Blood 13.2.2. Urine 13.2.3. Saliva 13.2.4. Others 13.3. Market Value Forecast, by Test Type, 2017–2031 13.3.1. Genetic Testing 13.3.1.1. Nutrigenetics Test 13.3.1.1.1. Weight Control 13.3.1.1.2. Lactose Intolerance 13.3.1.1.3. Others 13.3.1.2. Celiac Disease Test 13.3.1.3. Sports & Physical Activity Testing 13.3.1.4. Men's Health Tests 13.3.1.5. Women's Health Tests 13.3.1.6. Pregnancy & Prenatal Screening Test 13.3.1.7. General Health Testing 13.3.1.8. Others 13.3.2. Disease Risk Assessment Testing 13.3.2.1. Sexual Health Tests 13.3.2.1.1. HIV 13.3.2.1.2. Chlamydia 13.3.2.1.3. Others 13.3.2.2. Cancer Predisposition Tests 13.3.2.3. Others 13.3.3. CBC 13.3.4. Chronic Disease Testing 13.3.4.1. Diabetes Testing 13.3.4.2. Hypertension 13.3.4.3. Others 13.3.5. COVID-19 Testing 13.3.6. TSH Testing 13.3.7. Others 13.4. Market Value Forecast, by Provider, 2017–2031 13.4.1. Hospitals 13.4.2. Clinics 13.4.3. Speciality Labs 13.4.4. Diagnostic Centres 14. Rest of Europe Countries Direct-to-Consumer Laboratory Testing Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Sample Type, 2017–2031 14.2.1. Blood 14.2.2. Urine 14.2.3. Saliva 14.2.4. Others 14.3. Market Value Forecast, by Test Type, 2017–2031 14.3.1. Genetic Testing 14.3.1.1. Nutrigenetics Test 14.3.1.1.1. Weight Control 14.3.1.1.2. Lactose Intolerance 14.3.1.1.3. Others 14.3.1.2. Celiac Disease Test 14.3.1.3. Sports & Physical Activity Testing 14.3.1.4. Men's Health Tests 14.3.1.5. Women's Health Tests 14.3.1.6. Pregnancy & Prenatal Screening Test 14.3.1.7. General Health Testing 14.3.1.8. Others 14.3.2. Disease Risk Assessment Testing 14.3.2.1. Sexual Health Tests 14.3.2.1.1. HIV 14.3.2.1.2. Chlamydia 14.3.2.1.3. Others 14.3.2.2. Cancer Predisposition Tests 14.3.2.3. Others 14.3.3. CBC 14.3.4. Chronic Disease Testing 14.3.4.1. Diabetes Testing 14.3.4.2. Hypertension 14.3.4.3. Others 14.3.5. COVID-19 Testing 14.3.6. TSH Testing 14.3.7. Others 14.4. Market Value Forecast, by Provider, 2017–2031 14.4.1. Hospitals 14.4.2. Clinics 14.4.3. Speciality Labs 14.4.4. Diagnostic Centres 15. Competition Landscape 15.1. Market Player - Competition Matrix (by tier and size of companies) 15.2. Company Profiles 15.2.1. 23andMe, Inc. 15.2.1.1. Company Description 15.2.1.2. Business Overview 15.2.1.3. Strategic Overview 15.2.1.4. SWOT Analysis 15.2.2. Ancestry 15.2.2.1. Company Description 15.2.2.2. Business Overview 15.2.2.3. SWOT Analysis 15.2.3. CircleDNA 15.2.3.1. Company Description 15.2.3.2. Business Overview 15.2.3.3. SWOT Analysis 15.2.4. Eurofins Scientific 15.2.4.1. Company Description 15.2.4.2. Business Overview 15.2.4.3. Financial Overview 15.2.4.4. SWOT Analysis 15.2.5. Family Tree DNA (Gene by Gene) 15.2.5.1. Company Description 15.2.5.2. Business Overview 15.2.5.3. SWOT Analysis 15.2.6. Laboratory Corporation of America Holdings 15.2.6.1. Company Description 15.2.6.2. Business Overview 15.2.6.3. Financial Overview 15.2.6.4. Strategic Overview 15.2.6.5. SWOT Analysis 15.2.7. Living DNA Ltd. 15.2.7.1. Company Description 15.2.7.2. Business Overview 15.2.7.3. SWOT Analysis 15.2.8. Medichecks.com Ltd. 15.2.8.1. Company Description 15.2.8.2. Business Overview 15.2.8.3. SWOT Analysis 15.2.9. MyHeritage Ltd. 15.2.9.1. Company Description 15.2.9.2. Business Overview 15.2.9.3. SWOT Analysis 15.2.10. MyMedLab, Inc. 15.2.10.1. Company Description 15.2.10.2. Business Overview 15.2.10.3. SWOT Analysis 15.2.11. Quest Diagnostics Incorporated 15.2.11.1. Company Description 15.2.11.2. Business Overview 15.2.11.3. Financial Overview 15.2.11.4. Strategic Overview 15.2.11.5. SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(金融)の最新刊レポート
Transparency Market Research社の金融分野での最新刊レポート
本レポートと同じKEY WORD(laboratory)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |